TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.86
−2.73%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.89
From 52W high−82.74%
Volume111486.00
Market cap$11.51M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 29, 2026
Open
$0.89
From 52W high
−82.74%
Volume
111486.00
Market cap
$11.51M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
30.6
MomentumView details →
1D Return
−2.73%
YTD Return
−79.65%
SummaryUpdated Jun 1, 2026
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company founded to develop innovative oral therapies for fibrosis-driven diseases. The company went public in April 2025 and focuses specifically on targeting the STAT3 pathway, a critical cellular signaling mechanism involved in inflammation and tissue scarring. Tvardi's approach centers on developing small molecule drugs that can be taken orally, offering potential advantages over injectable treatments commonly used in serious fibrotic conditions.
Similar companies
Latest newsMore news →
Tvardi Therapeutics announced the publication of preclinical data in the International Journal of Molecular Sciences supporting its STAT3 inhibitors, including TTI-109, for ulcerative colitis.36d agoTvardi Therapeutics reported a net loss of $6.5 million for Q2 2026, compared with net income of $4.2 million in Q2 2025, with research and development expenses of $4.0 million and general and administrative expenses of $2.6 million.78d ago